

*Together, we can provide better health
to people everywhere.*

TOP STORIES

WBBA Summer Social Caribbean Holiday this Thursday!

There's still time to register for the WBBA Summer Social on Thursday, July 12. Online registration closes soon, so hurry! "Caribbean Holiday," the 9th annual WBBA Summer Social, will feature steel drum band Bakra Bata, delicious Caribbean-inspired appetizers, various beverages and fun and creative sponsor displays (sponsors are listed on page 8 of this newsletter). Lucky winners of the "Wildest Hawaiian Shirt Contest, Male & Female Categories" will take the grand prize of appearing onstage to play the last song with Bakra Bata, regardless of musical aptitude. You will not want to miss this! WBBA members and prospective core members come for just \$35 and non-members and walk-ins pay \$75. If you haven't already done so, register *now* for the Summer Social at <http://www.washbio.org>.



Bakra Bata Steel Drum Band

Come to the Free WBBA Wellness Forum on August 2

"Get Well Now" is the theme of the 2007 WBBA Wellness Forum on Thursday, August 2 in downtown Seattle, sponsored by **Wells Fargo Insurance Services, Premera Blue Cross and Inland Northwest Health Services (INHS)**. Executives, HR staff, benefits

For every \$1 spent on wellness programs, employers can expect a return of \$2.30 to \$10.10 through lower medical claims, reduced absenteeism, improved productivity and other factors.

-- American Journal of Health Promotion Study

professionals and others who want to learn more about wellness in the workplace are invited to this free breakfast panel. Moderated by **Nancy Vorhees**, CEO of NW Health Partners-INHS, the panel will feature **Bob Lutz, MD, MPH**,

Medical Director of Health@Work, Community Health Education & Resources; **Dr. Dave Johnson**, Regional Medical Director for Disease Management, Health Risk Management & Population Health, Premera; and representatives from small and large companies with successful Wellness Programs. The panel is from 9 – 11 am, but if you can arrive early, you may also schedule a free personal biometric screening. Sign up for a biometric screening and/or register for "Get Well Now" by emailing bryan_marshall@wellsfargo.com.

Golf at Newcastle with WBBA on August 17

Golfers wanted! WBBA's Third Annual Golf Invitational will be the morning of Friday, August 17 at beautiful Newcastle-China Creek. Playing the links is fun, but if your company wants *more* exposure among C-level executives, consider sponsoring a hole (\$1,200, includes one player) or have your logo on every golf cart as a "Golf Cart Sponsor" (\$2,000). Current sponsors include **Townsend and Townsend and Crew LLP** (Premier Sponsor); **Lease Crutcher Lewis** (Beverage Cart Sponsor); **Seed IP Law Group PLLC** (Photo Sponsor); **Oracle** (Lunch Sponsor) and Hole Sponsors: **BNBuilders, Employer Resources Northwest, Merck & Co, Inc, Perkins Coie, Prudential Cleanroom Services** and **Wells Fargo Insurance Services**. Contact Pam Love, pamlove@washbio.org about sponsorship or visit www.golf-events.com/wbbagolf to register as an individual, foursome or as a Hole Sponsor.



Governor's Life Science Summit September 27

Washington's life science companies and researchers have had a terrific year since the 2006 Governor's Life Science Summit. The comprehensive plan for the life sciences

JULY 9, 2007

WBBA PLATINUM LEADERS

Amgen
DLA Piper US LLP
Gilead Sciences
Heller Erhman LLP
Kirkpatrick & Lockhart
Preston Gates Ellis LLP
Lane Powell PC
Merck & Co., Inc.
Moss Adams LLP
Orrick, Herrington
& Sutcliffe, LLP
Perkins Coie LLP
University of Washington
Wells Fargo Insurance Services
(formerly Acordia)

WBBA GOLD LEADERS

Airgas Specialty Gas Division
Alexandria Real Estate Equities, Inc.
Battelle Pacific Northwest Division
Benaroya Research Institute
Bill & Melinda Gates Foundation
BNBuilders, Inc.
Cardiac Science, Inc.
Darby & Darby PC
Davis Wright Tremaine LLP
Dendreon Corporation
Dorsey & Whitney LLP
Ernst & Young LLP
Fred Hutchinson Cancer
Research Center
Hillis Clark Martin & Peterson
Inland Northwest Health Services
Institute for Systems Biology
KPMG LLP
Lease Crutcher Lewis
Microsoft
NBBJ
Parker | Smith | Feek
Philips Ultrasound
Premera Blue Cross
PricewaterhouseCoopers LLP
Seattle Children's Hospital & Research
Institute
Sellen Construction
Silicon Valley bank
Skanska USA Building, Inc.
SonoSite
Swedish Research Division at
Swedish Health Services
Townsend and Townsend
and Crew LLC
Turner Construction Co.
Vulcan Inc.
Washington State University
Woodcock Washburn LLP
ZymoGenetics, Inc.

WBBA OFFICERS

Chair
James Gore
Immediate Past Chair
Bruce Montgomery, MD
Gilead Sciences

Secretary
Kevin Kelly
Heller Ehrman LLP

Treasurer
Erick Rabins
Onconome, Inc.

President
Jack Faris, PhD
WBBA

("The Future of Life Sciences in Washington") launched at the second Summit, is underway. The first round of proposals for the Life Science Discovery Fund has been released, and the life sciences are a key part of Governor Gregoire's statewide business plan, "The Next Washington." This year's Governor's Life Science Summit will include an update on Life Science's Discovery Fund activities, a review of progress toward the comprehensive plan for life sciences with a particular focus on regions around the state, and an opportunity for you to provide input on the priorities of the comprehensive plan for 2008.

Sellen Construction is WBBA's Newest Gold Leader

Welcome to **Sellen Construction** which recently joined WBBA as our newest **Gold Leader** member. Sellen is among the largest locally owned commercial construction firms in the Pacific Northwest. They work with a collection of world-class companies, organizations, and public institutions on life science/ research, healthcare, higher education, commercial office, and tenant improvement projects. Sellen offers expertise in developing solutions that address the critical issues associated with successful laboratory facilities: comprehensive system integration and coordination, technical performance criteria, special floor height requirements, indoor air quality, and start-up testing and commissioning requirements. For more information contact **Erik Westover** at eric.westover@sellen.com or 206-571-1803, or visit <http://www.sellen.com>.

"Challenges of Setting Up in India" to be Explored August 16

Kiran Mazumdar, an expert on Biotech in India said, "US biotech companies have a very hard time. It's a high risk business. If you succeed, it's a bonanza, but if you fail it's a disaster" (from *'Planet India'*). **Vivek Sekhar** of **Chase-Hub Consulting** has created a short seminar that will cover how you can use India to build ideas, business value and profits for your company as well as ways to use India to mitigate risk, stretch the dollar and increase your success rate. Topics include: entry level setup; understanding costs and possibilities such as outsourcing, off-shoring, contract R&D, leveraging strengths and joint ventures. Attend this seminar to learn how to take advantage of India and not kill or shelve your idea due to costs and other factors. Chase-Hub Consulting specializes and supports the establishment of high tech companies in India. This new seminar is from 7:30 – 9 am on Thursday, August 16 at the WBBA office. For more information or to register, contact Vivek Sekhar at chaseusa@gmail.com.

What: "Challenges of Setting Up in India – Ground Realities for Life Science Companies"

When/Where: 7:30 – 9 am, Thursday, August 16, WBBA Offices, 2324 Eastlake Ave E, Suite 500, Seattle 98102

Registration: \$25 for WBBA members; register by email with Vivek Sekhar at chaseusa@gmail.com.

Introducing Two New WBBA Business Solutions Purchasing Partners

WBBA Business Solutions saved WBBA member companies thousands of dollars in partnership discounts over the last quarter on such services as lab supplies/equipment; employee benefits; worker's comp insurance refunds; shipping and others. We are proud to announce two new Purchasing Partners with the WBBA Business Solutions program:

Prudential Cleanroom Services is the latest member of the WBBA Business Solutions purchasing consortium. Since 1960, Prudential has been recognized as a leader in clean room laundry processing services. Prudential provides clean room garment processing services for particulate and ESD controlled environments – ISO 9001: 2000 certified.

PCS Cleanroom garment processing facilities are validated for sterile garment processing. Prudential is able to provide national or international cleanroom laundry and industrial apparel service programs and is committed to satisfying the evolving requirements of WBBA members. Learn more about PCS Cleanroom at Hole #18 at the [WBBA Golf Invitational](#) on August 17. For a free consultation and estimate, which will include a discount for WBBA members, please contact **Clayton W. Foutch**, Sr. Account Executive at 503-590-7023.



WBBA's other new partner – **Business Wire** – is a wholly owned subsidiary of Berkshire Hathaway, official partner of BIO, and global market leader in commercial news distribution. Thousands of companies depend on Business Wire to transmit their full-text news releases, regulatory filings, photos and other multimedia content to journalists, financial professionals, investor services, regulatory authorities and the general public worldwide. Business Wire's trade show and conference division provides integrated communications tools to public relations and investor relations professionals. Learn more about Business Wire at their display at the [WBBA Summer Social](#) on July 12 or visit <http://www.businesswire.com>. You can also call **Brad Heinrich**, Northwest Regional Manager, at 800-371-2638 or email him at brad.heinrich@businesswire.com.

2007 Pacific Health Summit was the “Best Yet”

The third Pacific Health Summit on June 12-14, was the “best yet,” said WBBA President **Jack Faris, PhD**. A highlight was the announcement of the creation of the **Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery** with a \$15 million commitment by Lilly. Partners in this effort include Afya World Medicines, the **Infectious Disease Research Institute, Jubilant Biosys, Merck & Co., Seattle Biomedical Research Institute**, and the **University of Washington Department of Global Health**. Afya World Medicines was created by a group of medicinal chemists formerly employed by ICOS. The partnership will conduct early-phase discovery research of new medicines urgently needed to treat tuberculosis, including emerging resistant strains. Keynote speakers at the Summit included former Sen. Sam Nunn; **Dr. Lee Hartwell**, President of the **Fred Hutchinson Cancer Research Center**; **Tachi Yamada**, President, Global Health Program, **Bill & Melinda Gates Foundation**; Andrew Von Eschenbach, FDA Commissioner; Joe Hogan, CEO, GE Healthcare; Jean Stephenne, President & General Manager, GlaxoSmithKline; David Nabarro, UN System Senior Coordinator for Avian and Human Influenza; UN Development Group; **Craig Mundie**, Chief Research & Strategy Officer, **Microsoft**; and Margaret Chan, Director-General, W.H.O.

Life Sciences Central Internship and Education Resource

As a summer intern at WBBA and a Junior majoring in biology at the University of Pennsylvania, **Caiti Smukowski** has faced the difficulty of finding internships and summer jobs in the life sciences field. This experience inspired her to create an internship resource for high school and undergraduate students in Washington State. This summer she is working with WBBA, the **Workforce Development Council of Seattle/King County**, and the **Northwest Association for Biomedical Research** to create a comprehensive online resource identifying opportunities for students to acquire firsthand experience in life science companies across the state. Smukowski said, “Interns can help staff and scientists meet project goals, bring new ideas to the workplace and provide a flexible, cost effective work force in labs and offices while not requiring a long-term employer commitment. You can help! If your company has an existing internship program for high school or undergrad students, or is interested in creating one, please contact me.” Not able to provide internships? Consider offering a job shadow program, hosting volunteers, or providing site tours. To share ideas for the development of this resource, contact caiti@washbio.org. The goal is to have an internship resource up on www.ls-central.com by late August.



AdvaMed October 1 – 3 in WA DC

AdvaMed 2007 is the premier medical technology conference and exhibition for business leaders, policymakers, investors, news media, patient advocates, and industry stakeholders from around the world. This year’s conference offers a variety of workshops and panel discussions on subjects such as Medicare reimbursement, compliance, intellectual property, global market opportunities, corporate finance, public policy, emerging company issues, 21st century health care and the value of medical technology. Whether you need to finance, partner or license technology, AdvaMed 2007 introduces you to key decision-makers – featuring a business development program, an investor forum for emerging growth companies, and an exhibition showcasing the latest medical technologies and products. Attendees will have the opportunity to directly access key players, inform stakeholders as to the progress of our industry, and influence the business, political and financial climates so imperative to innovation. Learn more or register at <http://www.advamed2007.com/index.cfm?page=180>.



Hurry – You Can Still Register for the Children’s Bioethics Conference July 13-14

The **Treuman Katz Center for Pediatric Bioethics at Seattle Children’s Hospital** hosts its third annual conference on July 13-14, 2007 in Seattle. Participants will discuss how to navigate conflicts that occur when parents and providers disagree about medical care. National experts will lead discussions on physicians refusing to provide life-prolonging interventions, listing developmentally delayed children for organ transplantation, using children as a means to a sibling’s health, parents refusing treatment for newborns, and the use of complementary medicine in pediatric patients. “Conflicts between parents and healthcare providers reflect differing opinions about how to weigh the benefits and burdens of certain medical interventions,” said **Dr. Benjamin Wilfond**, the Center’s Director. This conference addresses ethical questions related to navigating conflicts between parents and medical providers. For more information visit <http://www.seattlechildrens.org/bioethics/>.

Women Entrepreneurs Note: Call for Applications from Astia

Astia (formerly The Women's Technology Cluster) is seeking women-led companies in the life science, high tech and clean tech sectors to apply to present at the 6th Annual Venture Conference on October 18 in Silicon Valley. Astia's Venture Conference is the premier event for women-led companies seeking VC investment in Series A to D and beyond. Astia invests heavily in companies seeking Series A by providing them with the Astia Funding Series, led by VC panelists and including valuable hands-on coaching. Presenting companies are coached by CEOs and VCs, angels and successful entrepreneurs. Participants may pitch to an audience of 250 attendees, including 60 + Silicon Valley VC firms. For information, visit www.astia.org/venture_conference. Application deadline is August 10.

WELCOME NEW MEMBERS

American Pacific Relocation works with organizations to manage employee relocations in a way that fits each individual culture and financial structure. They help companies maximize the value of the dollars spent on relocation by allowing employees to focus on their jobs, alleviating stress and worry for them and their families and by providing a move coordinator 24/7, saving time and money to the company. American Pacific Relocation offers many services such as: home finding, temporary living, mortgage assistance, spouse career services, rental options, area tours, destination orientation, home selling, household goods shipment, storage, auto shipping, pet transportation, program design, policy consulting and development, and RFI & RFP process. For more information, contact **Christy Short** at cshort@ampacrelo.com or 206-267-8810.

APCO Worldwide is a full service public affairs and strategic communications firm in Seattle, Washington, headquartered in Washington DC. They provide clients with an array of communications services to help them tell their story and deliver their messages effectively to their audiences: customers, investors, legislators, partners, stakeholders, the media, and other key decision-makers. APCO's clients include seven of the top 10 Fortune 500 companies, most of whom turn to APCO for strategic counsel and corporate communications programs to manage business, financial, and public policy issues and perceptions. APCO was named PR Agency of the Year 2006 by PR Week and Best Agency in Public Affairs by The Holmes Report. For more information, contact **Jake Johnston** at jjohnston@apcoworldwide.com or 206-239-0159.

Coopersmith Health Law Group of Seattle, Washington is devoted exclusively to representing hospitals, physicians, organizations and individuals in their dealings with health insurance companies, health care regulators, and providers of health care. The firm is known for its industry knowledge, collaborative relationships with regulators and health insurance companies, and track record of positive and cost-effective results. For more information contact **Jeffrey Coopersmith** at info@coopersmithlaw.com or 206-343-1000.

GLY Construction is one of the largest locally owned general contractors in the Puget Sound, led by nine full-time principals who are actively involved in day-to-day operations. They have a strong focus on teamwork, which begins with a total commitment to their clients and is supported by skilled, innovative building professionals. GLY actively collaborates with owners, designers and facilities managers to exceed established objectives for cost, flexibility, schedule, and quality. Their achievements result in a significant number of repeat client relationships; over 75% of their business involves clients they have served on multiple projects. For more information, contact **Todd Gill** at todd.gill@gly.com.

Lewis Coaching & Consulting, a coaching and organizational development firm, was introduced in last month's NewsFacts with an incorrect email address. NewsFacts regrets the error. Please note the correct email for **Jane Lewis** is: janeclewis@comcast.net and her phone number is 206-686-7500.

Miller Nash LLP is a multi-specialty law firm that serves clients in the Pacific Northwest and around the world from offices in Seattle and Vancouver, Washington and Portland and Central Oregon. They serve a wide range of leading businesses, nonprofit organizations, public entities, and individuals. Their clients come from a variety of industries important to the region: agriculture, banking, biotechnology, communication, construction, education, energy, food processing, forest products, government, health care, high technology, manufacturing, real estate development, retail, shipping, transportation, and utilities. For more information contact **Steve McLean** at steve.mclean@millernash.com or 206-777-0766.

Paar Consulting, LLC provides real estate, construction management, and business consulting services to biotechnology, life sciences, and high-tech firms. Their team members have professionally established themselves in the industry and have earned graduate level degrees from highly accredited universities. **Joseph Paar**, founder, has

earned a Master in Business Administration (MBA) degree and a Construction Management degree, both from the University of Washington. For more information, contact **Joe Paar** at joepaar@gmail.com or 206-322-5415.

Xenocs is the leading independent supplier of X-ray optics and X-ray beam delivery systems, producing a wide range of X-ray components using sub-nanometer precision multi-layer coating technology and innovative single reflection optical concepts. Their products find use in a wide range of applications, including protein structure determination, semiconductor metrology, and characterization of nano-materials. Their products are tailored to meet clients' specific needs and are suited for applications such as X-ray diffraction (XRD), X-ray reflectometry (XRR), small angle X-ray scattering (SAXS), X-ray photo-electron spectroscopy (XPS), and X-ray spectroscopy, including wavelength dispersive X-ray fluorescence (WDXRF) and electron probe microanalysis (EPMA). For more information, contact **Brett Kraabel** at brett.kraabel@xenocs.com.

LIFE SCIENCE NEWS

Acucela was awarded a six-month, \$100,000 Phase I Small Business Innovation Research grant from the National Institutes of Environmental Health Sciences (part of the NIH). These competitive grants are designed to help small businesses develop and commercialize innovative technologies. The grant will help Acucela develop, validate and commercialize Ocuscreen, a proprietary retinal culture screening system, as a practical in vitro system for evaluating the health effects of environmental toxicants. Successful development and commercialization of technology for predicting compound toxicity would help assess safe levels of exposure, thereby reducing healthcare costs and producing safer working and living environments, as well as reducing the need for animal testing in this field.

Albany Molecular Research, Inc. (NASDAQ: AMRI) acquired two pharmaceutical manufacturing sites, along with additional land for expansion, in Aurangabad and Navi Mumbai, India for approximately \$11 million in cash. The existing facilities now manufacture a range of pharmaceutical intermediates and bulk active ingredients, including treatments for diabetes, heart disease and asthma. AMRI also has obtained additional land in Aurangabad and plans to invest approximately \$15 million to expand and upgrade manufacturing capabilities over the next three years.

Calypso Medical Technologies received ISO certification for its Calypso® 4D Localization System and Beacon® electromagnetic transponder manufacturing process. ISO 13485 sets standards ensuring a comprehensive management system is used for the design and manufacture of medical devices. The certification status by the ISO demonstrates Calypso meets an international set of standards and guidelines that are components of business transactions, global trade and regulatory requirements. The Calypso system uses proprietary electromagnetic technology in conjunction with implanted Beacon® electromagnetic transponders in the prostate, enabling doctors to accurately set up radiation therapy and monitor organ motion during radiation therapy.

Cell Therapeutics (Nasdaq: CTIC; MTAX) announced that **Dr. Jay Umbreit** has joined the Clinical Department as the new Medical Director of the XYOTAX/CT-2103 program. Umbreit takes the lead on the PGT307 trial, and is medical lead on the PIONEER report. Scott Stromatt, CTI's EVP, Clinical Development and Regulatory Affairs, said, "We are pleased to have Dr. Umbreit join our team and to bring his many years of experience to CTI." Umbreit comes to CTI most recently from PPD, a global contract research organization where he developed pharmaceutical products. Previously, he was a professor of medicine at both the University of South Alabama and Emory University in Atlanta.

Confirma appointed **Ward Sparacio** as Vice President of Sales. He will report to **Dan Bickford**, EVP of Sales and Marketing. Confirma has partnered with thousands of imaging centers since 2003, helping develop more standardized, high performance breast MRI programs that deliver premium patient care.

Seattle Children's Hospital Research Institute, the **University of Washington School of Medicine**, and Radboud University in Nijmegen, Netherlands researchers have identified a new genetic cause for Joubert syndrome (JS), an inherited condition that affects development of the cerebellum and brainstem, which coordinate movements and regulate basic functions (breathing, swallowing, heart rate etc.) Published in the June 10, 2007 issue of *Nature Genetics*, the study confirms key information about genetic changes that cause JS, conclusively placing JS in a class of recently identified ciliopathic conditions. Joubert syndrome can result in developmental delay, poor physical coordination, irregular breathing, visual impairment, kidney failure and extra digits. The discovery of mutation in the gene (RPGRIP1L) paves the way for definitive DNA testing that can more conclusively diagnose JS and also identify asymptomatic carriers who might unknowingly pass the condition on. "By discovering this gene, we're on the forefront of research changing how we think about brain, retina and kidney development," said **Dr. Dan Doherty**, co-author on the study, from the Division of Genetics & Developmental Medicine at Seattle Children's Hospital Research Institute.

Gilead Sciences, Inc. (Nasdaq:GILD) completed the \$1.0 billion stock repurchase program that was authorized by its Board of Directors in March 2006. Under the buyback program, Gilead acquired approximately 8.4 million shares of its common stock at an average price of \$65.13 per share, representing a total of \$544.9 million, in connection with a \$1.3 billion convertible notes offering completed in April 2006 and subsequently used the remaining \$455.1 million to acquire approximately 5.6 million shares of common stock at an average price of \$81.02 per share. Upon completion of the stock repurchase program on June 18, 2007, the company had approximately 468,090,700 shares outstanding, excluding stock options and unvested restricted shares.

Epigenomics AG (Frankfurt, Prime Standard: ECX) has reached a milestone in completing the work on an optimized assay procedure for its blood-based cancer screening tests. The most advanced of these, the colorectal cancer screening test, is now ready for its planned reference laboratory transfer. After having demonstrated the performance of its biomarker Septin 9 for the convenient and reliable detection of colorectal cancer in blood plasma, Epigenomics had focused on the improvement of the assay procedure used to process the patient blood plasma samples and measure the biomarker. Improvements included a simplified sample handling, reduction in the costs of goods by more than 70% and a considerable shortening of the total processing time.

Koronis Pharmaceuticals, Inc. announced the closing of a \$20 million Series D financing to further the development of antiviral therapeutics based on Viral Decay Acceleration. The financing was led by **Pacific Horizon Ventures** and joined by Asset Management Company. The Series D financing will support Phase IIa proof-of-concept studies for the company's lead product candidate, KP-1461, a novel, oral small-molecule therapeutic that works through Viral Decay Acceleration(TM) (VDA) for the treatment of human immunodeficiency virus (HIV) infection. The first of two planned Phase 2a trials is now underway, and the Company targets completion of the trials in 2008.

MediQuest Therapeutics has completed its confirmatory Phase III study of Vascana – a topical formulation designed to treat Raynaud's Disease. The study met its primary end point and demonstrated statistical significance, with $p = 0.008$ for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups. "With the conclusion of this clinical study, MediQuest is one step closer to submitting the Vascana New Drug Application to the FDA," said MediQuest President and CEO **Dr. Frederick Dechow**. "If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud's symptoms, providing clinicians with a needed treatment for patients."

Northwest Biotherapeutics, Inc. was advised by NASDAQ that, starting June 28, 2008, its shares of common stock will trade under the symbol NWBO with a CUSIP number 6637P501 and will reflect the effect of the one-for-fifteen reverse stock split which was previously announced and took effect on June 19, 2007. As a result of the reverse stock split, every 15 shares of Northwest Biotherapeutics' common stock were combined into one common share. No scrip or fractional certificates will be issued in connection with the reverse stock split. Stockholders who would be entitled to fractional shares will receive cash in lieu of receiving fractional shares. The reverse stock split resulted in similar adjustments to Northwest Biotherapeutics' outstanding common stock options and warrants and shares of common stock reserved for issuance pursuant to its current equity plans.

Pacific Biometrics, Inc. (PBI) (OTCBB: PBME) has been awarded a contract worth an estimated \$610,000 with a top multinational pharmaceutical company. This contract, related to a biological treatment for rheumatoid arthritis (RA), will provide essential laboratory data for a pivotal, global Phase III program.

Particle Measuring Systems (PMS) has acquired the particle counting division of Quest Technologies in Singapore. As a result, a newly created PMS sales and service center opened at the Techlink Building on Kaki Bukit Road recently. "Quest Technologies has done an excellent job of supporting the Singapore market for the past 20 years which provides a strong foundation upon which PMS will build for the future" said **Paul Kelly**, President. "We are very pleased to be transferring the employees from Quest to the Particle Measuring Systems organization to ensure the continuity of knowledge and service to support our customers". Particle Measuring Systems makes microcontamination monitoring devices and is celebrating its 35th Anniversary this year.

SCOLR Pharma, Inc. (AMEX: DDD - News) was issued a fifth patent from the USPTO entitled "Amino acid modulated extended release dosage form". SCOLR's amino acid-based technology is one of the patented/proprietary approaches within its CDT drug delivery platform for formulating novel tablets and capsules. The amino acid technology is designed to solve drug formulation challenges by controlling release of the active ingredient independent of the drug's solubility characteristics. In other news, the American Stock Exchange notified SCOLR Pharma on June 28 that it is not in compliance with the AMEX Company Guide. The AMEX letter states that the company does not have a sufficient number of independent directors such that a majority of its board is deemed to be

"independent" as defined in the AMEX Guide. This non-compliance is due to the unexpected death on April 20 of board member Dr. Michael Sorell, who had served as an independent director since April 2004. Additionally, Hans Mueller, PhD, an independent director since July 2005, did not stand for re-election. Consequently, the company's board currently consists of six directors, three of whom are independent. SCOLR Pharma has advised the AMEX that it intends to fill the vacancy on the board with qualified individuals as soon as reasonably possible.

SonoSite, Inc. (Nasdaq: SONO) filed a patent infringement lawsuit against General Electric Company (GE) and certain of its affiliates in the US District Court for the Western District of Wisconsin. The complaint is filed as a counterclaim to the complaint GE and its affiliates filed against SonoSite on May 15, 2007 in the same court. In parallel, SonoSite is filing its answer to the complaint denying all of GE's claims and alleging that the asserted patents are either invalid, not infringed, or both. In its counterclaim complaint, SonoSite asserts that GE and its affiliated companies infringe some SonoSite patents through their sales of ultrasound products, including GE's compact ultrasound systems. In other news, SonoSite, provided preliminary revenue results for the second quarter ended June 30, 2007. SonoSite said that worldwide revenue grew approximately 20 percent to over \$47 million compared to the second quarter of 2006. For the first half of 2007, worldwide revenue grew approximately 18% to about \$90 million compared with \$76.4 million for the first half of the prior year.

Targeted Genetics (Nasdaq CM: TGEN - News) has completed its private equity offering of 6.7 million shares of its common stock at a purchase price of \$2.905 per share, together with warrants to purchase up to an aggregate of 6.7 million shares of common stock, subject to adjustment pursuant to the terms of the warrants, at a price of \$3.25 per share of common stock. The gross proceeds from this financing were \$19.5 million, with net proceeds from the financing of approximately \$17.8 million after deducting the estimated costs associated with the transaction.

TranSenda International, LLC, has deployed its Clinical Trial Management System (CTMS) for Microbia, Inc. Microbia is in the process of enrolling patients for their two current Phase II dose-ranging studies. The Cambridge, MA-based pharmaceutical company had recognized that the combination of document folders, databases and spreadsheets that they had successfully utilized to manage the earlier phases of their trials would not adequately scale for subsequent phases, and therefore conducted a thorough search for a suitable solution. Designed for the unique needs of small- to mid-sized life sciences companies, the TranSenda CTMS was fully deployed at Microbia in March of 2007. TranSenda's CTMS will enable Microbia to take control of their trials using a collaborative web-based system that provides a central repository for the uniform tracking of key clinical processes and tasks, significantly reducing the manual requirements of study management and increasing employee effectiveness.

ZymoGenetics (Nasdaq: ZGEN) named **Douglas E. Williams, PhD** President of the company. **Bruce L.A. Carter, PhD**, will continue as ZymoGenetics' CEO and Chairman of the Board. **James A. Johnson** has been promoted to Executive Vice President and will remain Chief Financial Officer and Treasurer. **Darren R. Hamby** has been promoted to SVP, Human Resources. All three promotions were made effective July 1, 2007. "The promotions of Doug Williams, Jim Johnson and Darren Hamby recognize the increased contributions being made by these officers as we move into ZymoGenetics' next phase," said Carter. "It is an old saying that 'the more things change, the more they stay the same.' ZymoGenetics' business strategy remains to develop and commercialize recombinant Thrombin while, at the same time, investing in our novel genomics candidates: atacept, Interleukin 21 and PEG-Interferon lambda, as we continue to build the company for the future."

The University of Washington raised another \$5 million to fund its new stem cell institute but still lags behind other universities in the race for dollars to fund stem cell research. **Tom Ellison**, the Chairman of Savers Inc. of Bellevue, the parent company of Value Village, and his wife, Sue, are making the \$5 million donation. Their contribution brings the UW's total fundraising for the institute to more than \$17 million. The UW is one of many universities pushing for private dollars to fund human embryonic stem cell research in the face of continuing federal restrictions. President Bush, citing ethical concerns, vetoed a bill this month that would have lifted federal restrictions on such research. Ellison, who said some of his relatives suffered from Alzheimer's disease, said he was impressed by UW's stem cell faculty and felt it was important to keep the effort going.

UPCOMING EVENTS

- July 12** **WBBA Summer Social Caribbean Holiday** 4:30 – 7:30 pm, S. Lake Union Discovery Center, Seattle.
Visit <http://www.washbio.org> for a link to online registration; WBBA members \$35/nonmembers \$75.
- July 13-14** **Pediatric Bioethics Conference – Seattle Children's Hospital** <http://bioethics.seattlechildrens.org>
- July 31** **Summer in Seattle Cardiology Conference**, Westin Hotel, Seattle.

- Aug 2** "Get Well Now" Free WBBA Wellness Forum and Breakfast, complimentary biometric screening by appointment. Contact Bryan Marsh at Bryan_Marsh@wellsfargois.com to reserve your spot.
- Aug 16** "Challenges of Setting Up in India: Ground Realities for Life Science Companies" WBBA Office. For questions and to register, email Vivek Sekhar at Chase-Hub Consulting, chasehub@gmail.com.
- Aug 17** **WBBA Golf Invitational**, Newcastle China Creek, 8 am tee time followed by lunch. Hole sponsorships still available, contact pamlove@washbio.org. Non-sponsoring golfers may register online now.
- Sept 27** **Governor's Life Science Summit III**, Seattle.
- Oct. 30** **WBBA Annual Meeting**, Seattle. Save the date; look for more information on www.washbio.org soon.

ADVERTISEMENTS AND MARKETING OPPORTUNITIES

Looking for the Right Candidate? Need to Recruit Nationally? Advertise with the WaBio.com national network of state-based biotechnology web sites that represent more than 3,500 biotechnology and medical device companies, non-profit research institutions, universities and supporting service sector companies across the US. Cost effectively target your employee recruitment by state, region or nationwide for the same low rate. WBBA members receive a 15% discount off the standard advertising rate. WaBio.com job postings are \$175/mo. for WBBA members and you can now place your job postings with any or all of our affiliate state sites at "no additional charge." To learn more, access http://www.WaBio.com/ad/ad_jobs.htm or call 206-937-3620. Recruit better through WaBio.com.

Grants Available from the ALA – The American Lung Association Research Program 2008-2009 offers hundreds of thousands of dollars in grants to researchers conducting studies on lung cancer, patient care, diagnosis, sleep disorders, interstitial lung disease, pulmonary fibrosis, health policy, behavioral health, epidemiology, pediatric pulmonary and related issues and diseases. Deadline for application is September 4, 2007. For more information, please visit: <http://www.lungusa.org/site/pp.asp>.

Does your business have a technical challenge or task that could benefit from the expertise available at Pacific Northwest National Laboratory? You could be eligible for a week of **free technology assistance** annually from PNNL scientists and engineers. Through more than 700 projects over the years, PNNL has helped businesses in sectors including information technology, instrumentation and electronics, manufacturing, medical and biotechnology, agriculture, energy, environmental protection, and consumer products. Recipients consistently give very high marks for the quality of the assistance. Technology assistance projects for the rest of this fiscal year must be completed by the end of September 2007, so interested businesses should contact the Economic Development Office at PNNL as soon as possible. For more information, visit: http://www.pnl.gov/edo/business/tech_assistance.stm or contact **Gary Spanner** at (509) 372-4296 or gary.spanner@pnl.gov.

WaBio.com News Release Service -- Want to maximize your company's or organization's exposure? Submit your news release with WaBio.com and receive national exposure along with archiving services free of charge. This is a new service to support the dissemination of company and non-profit organization news. Upon submission your news release will be displayed in a rotational queue on the WaBio.com home page, and all news releases submitted will be archived as a historical research resource. To submit your news release, please complete the following: <http://www.wabio.com/addnews/>.

Caribbean Holiday 4:30 – 7:30, Thursday July 12...[Register Now!](#)

Thanks to our sponsors:

ABD Financial Services	Airgas Specialty Gas Division	BarclayDean
BNBuilders	Congruent Software	Diamond Cleaning Services
Graphica	Lane Powell, PC	Leewans Corporation
On Assignment Lab Support	PuRODI Systems	Seed Intellectual Property Law Group PLLC
Vulcan Inc.	Wells Fargo Insurance Services	PEDOMETER SPONSOR: AirVan



*Together, we can provide better health
to people everywhere.*

The Washington Biotechnology & Biomedical Association (WBBA) is working with leaders across the state to implement a comprehensive bioscience strategy for Washington's future.

NewsFacts is issued monthly except for December, depending on news volume, and sent to more than 1500 subscribers as a benefit of WBBA membership. Send news to Pam Love at pamlove@washbio.org. To unsubscribe, email to: kathleen@washbio.org with "NewsFacts unsubscribe" as the subject line. For more information, contact WBBA. Phone (206) 732-6700.

2324 Eastlake Ave. E., Suite 500
Seattle, WA 98102